As a healthcare provider, I want to add some clinical context to this discussion on Tirzepatide and fatty liver SURPASS.
Building on what MASHdoc_SA said — the evidence base here is well-established. The key publications to reference are from the SUSTAIN program[1].
Key clinical points:
- Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
- Side effect profile is predictable and usually manageable with standard protocols
- Monitoring should include baseline labs and follow-up at 3-month intervals
- Patient education significantly improves outcomes and adherence
Standard disclaimer: this is educational, not individualized medical advice.
[1] See thread title for relevant study identification.
mike_mod said:I have cleaned up a few off-topic posts
Gonna push back on this one. Tirzepatide and fatty liver is not that straightforward in my experience. I have been on this for 18 months and the reality is messier than the trials suggest.
Don't get me wrong — the medication works. But adherence is harder than people admit. We should be honest about that.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesWant to share my personal experience related to Tirzepatide and fatty liver since I think it might help others in a similar situation.
I started my GLP-1 journey in March 2025 at 259 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.
Now, 8 months later: I am down 89 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The Tirzepatide and aspect specifically was something that made a big difference in my journey.
This forum was my go-to resource throughout.
Saving this for reference. Quality thread.